2020
Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Journal Of Clinical And Translational Hepatology 2020, 8: 377-384. PMID: 33447520, PMCID: PMC7782110, DOI: 10.14218/jcth.2020.00039.Peer-Reviewed Original ResearchClinical outcome eventsHepatocellular carcinomaDiagnostic criteriaChronic hepatitis B virus infectionHepatitis B virus infectionPrimary study outcome measureHBV disease progressionNon-HCC malignanciesChronic hepatitis BB virus infectionStudy outcome measuresDisease progression eventsEvent adjudication committeePotential adverse effectsRandomized therapyAnalogue therapyHepatitis BProspective studyAdjudicated diagnosisAdjudication committeeMalignant neoplasmsDisease progressionEvent adjudicationOutcome eventsVirus infectionPrevalence of Chronic Hepatitis B Virus Infection in the United States.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of Chronic Hepatitis B Virus Infection in the United States. The American Journal Of Gastroenterology 2020, 115: 1429-1438. PMID: 32483003, DOI: 10.14309/ajg.0000000000000651.Peer-Reviewed Original ResearchConceptsChronic hepatitis B virus infectionHepatitis B virus infectionB virus infectionWorld Health OrganizationChronic HBVVirus infectionMajor global health problemChronic HBV infectionGlobal health problemHBV prevalenceHBV infectionHBV screeningLiver cirrhosisSubstantial morbidityLiver diseaseClinical complicationsHepatocellular carcinomaHealth problemsElimination planPrevalenceDisease FoundationHealth OrganizationInfectionPeer-reviewed literatureUnited States
2018
An expert consensus for the management of chronic hepatitis B in Asian Americans
Tong MJ, Pan CQ, Han S, Lu D, Raman S, Hu K, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Alimentary Pharmacology & Therapeutics 2018, 47: 1181-1200. PMID: 29479728, PMCID: PMC5900913, DOI: 10.1111/apt.14577.Peer-Reviewed Original ResearchConceptsChronic hepatitis BAnti-viral therapyHepatocellular carcinomaHepatitis BHBV DNAPregnant womenBasal core promoter mutationsNegative chronic hepatitis BHepatitis B virus infectionAsian American physiciansLiver related deathManagement of HBVDetectable HBV DNAHBeAg-negative patientsHBsAg-positive patientsHBV DNA levelsNormal ALT levelsB virus infectionCore promoter mutationsHBsAg carrier rateLife-long surveillanceContrast CT scanAbdominal ultrasound examinationAlpha-fetoprotein testingAsian American patients
2017
Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network
Kwak YE, Stein SM, Lim JK. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network. Digestive Diseases And Sciences 2017, 63: 61-71. PMID: 29177849, DOI: 10.1007/s10620-017-4850-1.Peer-Reviewed Original ResearchConceptsCommunity oncology clinicsCommunity teaching hospitalHBV screening rateOncology clinicTeaching hospitalHBV infectionScreening ratesCancer chemotherapyUniversity HospitalChronic hepatitis B virus infectionHepatitis B virus infectionHepatitis B Virus ScreeningHBV reactivation riskChronic HBV infectionB virus infectionHBV core antibodyHBV surface antigenAdult cancer patientsRisk of reactivationHospital networkLarge university hospitalCore antibodyHBV exposureHBV screeningBackgroundCancer patients
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration